ProShare Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-24,385
| Closed | -$439K | – | 1715 |
|
|
2020
Q2 | $439K | Buy |
24,385
+7,955
| +48% | +$111K | ﹤0.01% | 1018 |
|
|
2020
Q1 | $117K | Sell |
16,430
-12,414
| -43% | -$155K | ﹤0.01% | 1064 |
|
|
2019
Q4 | $689K | Sell |
28,844
-2,318
| -7% | -$63.9K | ﹤0.01% | 936 |
|
|
2019
Q3 | $836K | Buy |
31,162
+2,723
| +10% | +$76.4K | ﹤0.01% | 810 |
|
|
2019
Q2 | $772K | Sell |
28,439
-3,878
| -12% | -$122K | ﹤0.01% | 857 |
|
|
2019
Q1 | $1.12M | Buy |
32,317
+994
| +3% | +$28.7K | 0.01% | 720 |
|
|
2018
Q4 | $611K | Sell |
31,323
-5,924
| -16% | -$122K | ﹤0.01% | 878 |
|
|
2018
Q3 | $992K | Sell |
37,247
-555
| -1% | -$18.1K | 0.01% | 822 |
|
|
2018
Q2 | $1.43M | Sell |
37,802
-1,309
| -3% | -$50.1K | 0.01% | 711 |
|
|
2018
Q1 | $1.28M | Sell |
39,111
-6,244
| -14% | -$274K | 0.01% | 744 |
|
|
2017
Q4 | $2.21M | Buy |
45,355
+7,572
| +20% | +$383K | 0.02% | 585 |
|
|
2017
Q3 | $2.04M | Buy |
37,783
+2,935
| +8% | +$172K | 0.02% | 554 |
|
|
2017
Q2 | $1.96M | Sell |
34,848
-2,203
| -6% | -$88.2K | 0.02% | 566 |
|
|
2017
Q1 | $1.45M | Sell |
37,051
-9,027
| -20% | -$287K | 0.02% | 648 |
|
|
2016
Q4 | $1.03M | Buy |
46,078
+3,978
| +9% | +$77.7K | 0.01% | 758 |
|
|
2016
Q3 | $956K | Sell |
42,100
-7,833
| -16% | -$184K | 0.01% | 695 |
|
|
2016
Q2 | $1.18M | Buy |
49,933
+875
| +2% | +$21.6K | 0.02% | 670 |
|
|
2016
Q1 | $1M | Sell |
49,058
-2,685
| -5% | -$85.2K | 0.01% | 699 |
|
|
2015
Q4 | $2.66M | Buy |
51,743
+5,324
| +11% | +$258K | 0.03% | 421 |
|
|
2015
Q3 | $1.98M | Sell |
46,419
-999
| -2% | -$48.2K | 0.03% | 481 |
|
|
2015
Q2 | $2.16M | Sell |
47,418
-1
| -0% | -$40 | 0.03% | 489 |
|
|
2015
Q1 | $1.8M | Buy |
47,419
+6,050
| +15% | +$208K | 0.02% | 595 |
|
|
2014
Q4 | $1.17M | Buy |
41,369
+5,393
| +15% | +$150K | 0.01% | 783 |
|
|
2014
Q3 | $909K | Sell |
35,976
-6,963
| -16% | -$183K | 0.01% | 1105 |
|
|
2014
Q2 | $1.25M | Buy |
42,939
+1,496
| +4% | +$36.2K | 0.02% | 1053 |
|
|
2014
Q1 | $1.07M | Buy |
41,443
+23,224
| +127% | +$620K | 0.01% | 1253 |
|
|
2013
Q4 | $469K | Buy |
+18,219
| New | +$443K | 0.01% | 1078 |
|
ProShare Advisors's PTLA Position: Q3 2020 in Review
ProShare Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 24,385 shares — an estimated $439K sold.
ProShare Advisors first reported a position in PTLA in Q4 2013 and held it in 27 quarters. The position peaked at $2.66M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- ProShare Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- ProShare Advisors sold 24,385 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $439K.
- ProShare Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 27 quarters.
- ProShare Advisors's Portola Pharmaceuticals, Inc. position peaked at $2.66M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on ProShare Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.